Indivior Pharmaceuticals, Inc. INDV Sublingual & other — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's sublingual & other — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's sublingual & other — net revenue?
- Indivior Pharmaceuticals, Inc. (INDV) reported sublingual & other — net revenue of $50M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's sublingual & other — net revenue changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's sublingual & other — net revenue decreased by 7.4% year-over-year, from $54M to $50M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's sublingual & other — net revenue?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's sublingual & other — net revenue has grown at a -11.2% compound annual growth rate (CAGR), from $323M to $226M.
- What does sublingual & other — net revenue mean?
- This metric represents the total net revenue generated from the company's sublingual and legacy product portfolio, excluding primary growth drivers. It reflects the performance of mature or non-core pharmaceutical assets within the substance use disorder treatment segment. Monitoring this figure helps investors assess the revenue decay or stability of established product lines as the company shifts focus toward newer therapeutic offerings.